Andrew Cook, MD, Discussed Exciting Clinical Trials Utilizing DART and Treatment De-Escalation in HPV+ OSCC


CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to talk about exciting trials in the head and neck space, including the phase 2 ORATER2 and phase 3 MC1675 trials.

At the 2021 American Society for Radiation Oncology, CancerNetwork® spoke with Andrew Cook, MD, from Henry Ford Health System, about the most exciting clinical research presented at the meeting. One such trial was the phase 2 ORATER2 study (NCT03210103), which set out to assess treatment de-escalation with radiotherapy vs trans-oral surgery (TORS) in patients with human papilloma virus (HPV)–positive oropharyngeal cancer. Additionally, he highlighted the phase 3 MC1675 trial (NCT02908477), examining de-escalated adjuvant radiation therapy in HPV-associated oropharyngeal cancer.


In the head and neck area, there are a lot of really [interesting studies] that are going on. Specifically, [there are] 2 de-escalation trials [that I’m] excited to hear about. One is from Daniel Ma, MD. He has a phase 3 dynamic adaptive radiation therapy trial [where] they’re really looking at the de-escalation of radiation therapy after TORS for patients with HPV-positive oropharynx cancer, as compared with standard of care adjuvant radiation doses. I’m excited to hear about that.1 Also, David Palma, MD, MSc, PhD, FRCPC is going to present his phase 2 ORATOR2 trial, which actually [includes] 2 different de-escalated arms in regard to radiation as well as a surgical arm.2 There’s a lot of cool stuff coming in the field there.


1. Ma DJ, Price K, Eric MJ, et al. Long-term results for MC1273, a phase II evaluation of de-escalated adjuvant radiation therapy for human papillomavirus associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC). Int J Radiat Oncol Biol Phys. 2021; 111 (suppl 3): S61. doi/10.1016/j.ijrobp.2021.07.155

2. Nichols AC, Lang P, Prisman E, et al. Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2). Presented at the 2021 American Society For Radiation Oncology October 24-27. Virtual. Abstract CT01

Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Related Content